Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses
I'm LongbridgeAI, I can summarize articles.Chugai Pharmaceutical has filed with Japan’s Ministry of Health, Labour and Welfare (MHLW) for regulatory approval to expand the indication of Enspryng. The filing aims to prevent relapses in patients with MOG antibody-associated disease (MOGAD). This application is supported by global Phase III study data demonstrating a 68% reduction in relapse risk compared to placebo.
- Chugai filed with Japan’s MHLW for an additional Enspryng indication to prevent relapse in MOG antibody-associated disease. * The filing is backed by a global Phase III study showing a 68% relapse-risk reduction versus placebo. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here